Nitric oxide donors improve the ovulation and pregnancy rates in anovulatory women with polycystic ovary syndrome treated with clomiphene citrate: A RCT
- PMID: 27141543
- PMCID: PMC4837925
Nitric oxide donors improve the ovulation and pregnancy rates in anovulatory women with polycystic ovary syndrome treated with clomiphene citrate: A RCT
Abstract
Background: Clomiphene citrate (CC) is the first line agent used for ovulation induction in patients with polycystic ovarian syndrome (PCOS). However, there is marked discrepancy between the ovulation and pregnancy rates achieved, which may be attributed to the undesirable effect of CC on cervical mucus and endometrium.
Objective: The aim of this study was to evaluate the effect of Isosorbid monoitrate (ISMN) as nitric oxide (NO) donors on the ovulation and pregnancy rates in an ovulatory women with PCOS treated with CC.
Materials and methods: Ninety patients with PCOS were randomly allocated into three groups. Patients in group A) were treated with 100 mg CC for five days starting from the fifth day of the cycle. Patients in group B) and C) received 10 mg and 20 mg of ISMN respectively in addition to CC, applied vaginally till the diagnosis of ovulation.
Results: There was a significant increase in the ovulation and pregnancy rates in the patients treated with CC+ISMN as compared with patients treated with CC alone (p< 0.001).
Conclusion: Concomitant use of NO with CC seems to improve the ovulation and pregnancy rates in the patients with PCOS with no significant increase in side effects as compared with CC alone.
Keywords: Clomiphene citrate; Nitric oxide donors; Polycystic ovary syndrome.
Conflict of interest statement
The authors declare that there is no conflict of interest in this paper.
Similar articles
-
Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome.Hum Reprod. 2017 Aug 1;32(8):1631-1638. doi: 10.1093/humrep/dex227. Hum Reprod. 2017. PMID: 28854590 Free PMC article. Clinical Trial.
-
First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis.Hum Reprod Update. 2019 Nov 5;25(6):717-732. doi: 10.1093/humupd/dmz029. Hum Reprod Update. 2019. PMID: 31647106
-
Pretreatment and co-administration of oral anti-diabetic agent with clomiphene citrate or rFSH for ovulation induction in clomiphene-citrate-resistant polycystic ovary syndrome.J Obstet Gynaecol Res. 2013 May;39(5):966-73. doi: 10.1111/j.1447-0756.2012.02072.x. Epub 2013 Feb 4. J Obstet Gynaecol Res. 2013. PMID: 23379651 Clinical Trial.
-
Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome.Cochrane Database Syst Rev. 2020 Feb 11;2(2):CD001122. doi: 10.1002/14651858.CD001122.pub5. Cochrane Database Syst Rev. 2020. PMID: 32048270 Free PMC article.
-
Molecular Mechanisms of Laparoscopic Ovarian Drilling and Its Therapeutic Effects in Polycystic Ovary Syndrome.Int J Mol Sci. 2020 Oct 31;21(21):8147. doi: 10.3390/ijms21218147. Int J Mol Sci. 2020. PMID: 33142702 Free PMC article. Review.
Cited by
-
Vasodilators for women undergoing fertility treatment.Cochrane Database Syst Rev. 2025 Mar 6;3(3):CD010001. doi: 10.1002/14651858.CD010001.pub4. Cochrane Database Syst Rev. 2025. PMID: 40047216
-
Female sexual behavior is disrupted in a preclinical mouse model of PCOS via an attenuated hypothalamic nitric oxide pathway.Proc Natl Acad Sci U S A. 2022 Jul 26;119(30):e2203503119. doi: 10.1073/pnas.2203503119. Epub 2022 Jul 22. Proc Natl Acad Sci U S A. 2022. PMID: 35867816 Free PMC article.
-
Vasodilators for women undergoing fertility treatment.Cochrane Database Syst Rev. 2018 Oct 12;10(10):CD010001. doi: 10.1002/14651858.CD010001.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2025 Mar 06;3:CD010001. doi: 10.1002/14651858.CD010001.pub4. PMID: 30312988 Free PMC article. Updated.
-
Human immunodeficiency: Extragonadal comorbidities of infertility in women.Immun Inflamm Dis. 2020 Sep;8(3):447-457. doi: 10.1002/iid3.327. Epub 2020 Jul 3. Immun Inflamm Dis. 2020. PMID: 32621331 Free PMC article. Review.
-
Matrix metalloproteinase-9 increases and Interleukin-10 reduces with increase in body mass index in polycystic ovary syndrome: A cross-sectional study.Int J Reprod Biomed. 2020 Aug 19;18(8):605-610. doi: 10.18502/ijrm.v13i8.7502. eCollection 2020 Aug. Int J Reprod Biomed. 2020. PMID: 32923927 Free PMC article.
References
-
- Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endorcinol Metab. 2004;89:2745–2749. - PubMed
-
- Thessaloniki ESHRE/ASRM-Sponsered PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462–477. - PubMed
-
- De Pace V, Chiossi G, Facchinetti F. Clinical use of nitric oxide donors and L-arginine in obstetrics. J Matern Fetal Neonat Med. 2007;20:569–579. - PubMed
-
- Tsukimori K, Komatsu H, Fukushima K, Kaku T, Nakano H, Wake N. Inhibition of nitric oxide synthetase at mid-gestation in rats is associated with increases in arterial pressure, serum tumour necrosis factor-alpha, and placental apoptosis. Am J Hypertens. 2008;21:477–481. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources